PURETECH HEALTH PLC - ADR (PRTC) Fundamental Analysis & Valuation
NASDAQ:PRTC • US7462371060
Current stock price
17.85 USD
-0.2 (-1.11%)
Last:
This PRTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRTC Profitability Analysis
1.1 Basic Checks
- PRTC had negative earnings in the past year.
- In the past year PRTC has reported a negative cash flow from operations.
- The reported net income has been mixed in the past 5 years: PRTC reported negative net income in multiple years.
- In the past 5 years PRTC always reported negative operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 9.16%, PRTC belongs to the best of the industry, outperforming 93.02% of the companies in the same industry.
- With an excellent Return On Equity value of 13.48%, PRTC belongs to the best of the industry, outperforming 93.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROIC | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PRTC's Profit Margin of 792.96% is amongst the best of the industry. PRTC outperforms 99.61% of its industry peers.
- PRTC's Profit Margin has declined in the last couple of years.
- PRTC does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
2. PRTC Health Analysis
2.1 Basic Checks
- PRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, PRTC has less shares outstanding
- Compared to 5 years ago, PRTC has less shares outstanding
- The debt/assets ratio for PRTC is higher compared to a year ago.
2.2 Solvency
- PRTC has an Altman-Z score of 1.77. This is a bad value and indicates that PRTC is not financially healthy and even has some risk of bankruptcy.
- PRTC's Altman-Z score of 1.77 is fine compared to the rest of the industry. PRTC outperforms 63.95% of its industry peers.
- A Debt/Equity ratio of 0.05 indicates that PRTC is not too dependend on debt financing.
- PRTC has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.77 |
ROIC/WACCN/A
WACC9.47%
2.3 Liquidity
- A Current Ratio of 8.49 indicates that PRTC has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 8.49, PRTC is in the better half of the industry, outperforming 73.64% of the companies in the same industry.
- A Quick Ratio of 8.49 indicates that PRTC has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 8.49, PRTC is in the better half of the industry, outperforming 73.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 |
3. PRTC Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 168.34% over the past year.
- The earnings per share for PRTC have been decreasing by -32.49% on average. This is quite bad
- Looking at the last year, PRTC shows a very strong growth in Revenue. The Revenue has grown by 1265.60%.
- The Revenue for PRTC have been decreasing by -13.22% on average. This is quite bad
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
3.2 Future
- Based on estimates for the next years, PRTC will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.98% on average per year.
- Based on estimates for the next years, PRTC will show a very strong growth in Revenue. The Revenue will grow by 223.14% on average per year.
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. PRTC Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PRTC. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as PRTC's earnings are expected to decrease with -17.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
5. PRTC Dividend Analysis
5.1 Amount
- PRTC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PRTC Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:PRTC (4/22/2026, 3:16:45 PM)
17.85
-0.2 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)04-29 2026-04-29/amc
Inst Owners69.22%
Inst Owner Change0%
Ins Owners4.73%
Ins Owner ChangeN/A
Market Cap434.50M
Revenue(TTM)6.39M
Net Income(TTM)50.68M
Analysts84
Price Target70.21 (293.33%)
Short Float %0.07%
Short Ratio3.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.2%
PT rev (3m)0.2%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.66%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 67.99 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.16 | ||
| P/tB | 1.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.24
EYN/A
EPS(NY)-6.47
Fwd EYN/A
FCF(TTM)-4.12
FCFYN/A
OCF(TTM)-4.12
OCFYN/A
SpS0.26
BVpS15.45
TBVpS15.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 792.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-2.58%
ROA(5y)-2.71%
ROE(3y)-3.51%
ROE(5y)-3.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-23.72%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.49 | ||
| Quick Ratio | 8.49 | ||
| Altman-Z | 1.77 |
F-Score7
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)9.91%
Cap/Depr(5y)37.78%
Cap/Sales(3y)7.17%
Cap/Sales(5y)20.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.34%
EPS 3YN/A
EPS 5Y-32.49%
EPS Q2Q%-20.01%
EPS Next Y-40.93%
EPS Next 2Y-23.56%
EPS Next 3Y-17.46%
EPS Next 5Y-16.98%
Revenue 1Y (TTM)1265.6%
Revenue growth 3Y-34.76%
Revenue growth 5Y-13.22%
Sales Q2Q%542.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y223.14%
EBIT growth 1Y13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.57%
EBIT Next 3Y-5.38%
EBIT Next 5Y3.12%
FCF growth 1Y36.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.98%
OCF growth 3YN/A
OCF growth 5YN/A
PURETECH HEALTH PLC - ADR / PRTC Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for PURETECH HEALTH PLC - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to PRTC.
What is the valuation status of PURETECH HEALTH PLC - ADR (PRTC) stock?
ChartMill assigns a valuation rating of 0 / 10 to PURETECH HEALTH PLC - ADR (PRTC). This can be considered as Overvalued.
How profitable is PURETECH HEALTH PLC - ADR (PRTC) stock?
PURETECH HEALTH PLC - ADR (PRTC) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for PRTC stock?
The Earnings per Share (EPS) of PURETECH HEALTH PLC - ADR (PRTC) is expected to decline by -40.93% in the next year.
Is the dividend of PURETECH HEALTH PLC - ADR sustainable?
The dividend rating of PURETECH HEALTH PLC - ADR (PRTC) is 0 / 10 and the dividend payout ratio is 0%.